UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 1, 2012

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At May 7, 2012, 7,488,136,070 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarterly Period Ended

April 1, 2012

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended April 1, 2012 and April 3, 2011

Condensed Consolidated Statements of Comprehensive Income for the three months ended April 1, 2012 and April 3, 2011

Condensed Consolidated Balance Sheets as of April 1, 2012 and December 31, 2011

Condensed Consolidated Statements of Cash Flows for the three months ended April 1, 2012 and April 3, 2011

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

40

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

41

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

75

Item 4.

Controls and Procedures

75

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

76

Item 1A.

Risk Factors

76

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

77

Item 3.

Defaults Upon Senior Securities

77

Item 4.

Mine Safety Disclosures

77

Item 5.

Other Information

77

Item 6.

Exhibits

77

Signature

78

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(millions, except per common share data)

April 1,

2012

April 3,

2011

Revenues

15,405

16,502

Costs and expenses:

Cost of sales(a)

2,974

3,693

Selling, informational and administrative expenses(a)

4,133

4,503

Research and development expenses(a)

2,072

2,091

Amortization of intangible assets

1,420

1,376

Restructuring charges and certain acquisition-related costs

596

894

Other deductions net

1,657

827

Income from continuing operations before provision for taxes on income

2,553

3,118

Provision for taxes on income

750

894

Income from continuing operations

1,803

2,224

Discontinued operations net of tax

10

Net income before allocation to noncontrolling interests

1,803

2,234

Less: Net income attributable to noncontrolling interests

12

Net income attributable to Pfizer Inc.

1,794

2,222

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.24

0.28

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.24

0.28

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.24

0.28

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.24

0.28

Weighted-average shares Basic

7,537

7,982

Weighted-average shares Diluted

7,598

8,035

Cash dividends paid per common share

0.22

0.20

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(millions of dollars)

April 1,

2012

April 3,

2011

Net income before allocation to noncontrolling interests

1,803

2,234

Other Comprehensive Income

Foreign currency translation adjustments

263

1,589

Reclassification adjustments(a)

(7

263

1,582

Unrealized holding gains/(losses) on derivative financial instruments

427

307

Reclassification adjustments for realized gains(a)

(300

(510

127

(203

Unrealized holding gains/(losses) on available-for-sale securities

80

(36

Reclassification adjustments for realized losses(a)

17

10

97

(26

Benefit plans: Actuarial gains/(losses)

Reclassification adjustments related to amortization(b)

117

70

Reclassification adjustments related to curtailments and settlements, net(b)

120

51

Other

15

(87

253

34

Benefit plans: Prior service (costs)/credits and other

Reclassification adjustments related to amortization(b)

(19

(18

Reclassification adjustments related to curtailments and settlements, net(b)

(9

(11

Other

(2

(3

(30

(31

Other comprehensive income, before tax

710

1,356

Tax expense/(benefit) on other comprehensive income(c)

204

(28

Other comprehensive income before allocation to noncontrolling interests

506

1,384

Comprehensive Income

Comprehensive income before allocation to noncontrolling interests

2,309

3,618

Less: Comprehensive income attributable to noncontrolling interests

16

Comprehensive income attributable to Pfizer Inc.

2,301

3,602

(a)

Reclassified into Other deductions net in the Condensed Consolidated Statements of Income.

(b)

Generally reclassified into Cost of sales, Selling, informational and administrative expenses, and Research and development expenses in the Condensed Consolidated Statements of Income.

(c)

See Note 5B. Tax Matters: Taxes on Items of Other Comprehensive Income.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

April 1,

2012

Dec. 31,

2011

(Unaudited)

Assets

Cash and cash equivalents

2,934

3,182

Short-term investments

21,038

23,270

Accounts receivable, less allowance for doubtful accounts

14,182

13,608

Inventories

7,189

6,969

Taxes and other current assets

9,361

9,441

Assets of discontinued operations and other assets held for sale

159

101

Total current assets

54,863

56,571

Long-term investments

10,632

9,814

Property, plant and equipment, less accumulated depreciation

16,192

16,938

Goodwill

45,252

45,067

Identifiable intangible assets, less accumulated amortization

52,801

53,833

Taxes and other noncurrent assets

5,943

5,779

Total assets

185,683

188,002

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

5,526

4,018

Accounts payable

3,091

3,836

Dividends payable

1,796

Income taxes payable

1,930

1,013

Accrued compensation and related items

1,752

2,169

Other current liabilities

14,794

15,237

Total current liabilities

27,094

28,069

Long-term debt

33,543

34,931

Pension benefit obligations

6,181

6,355

Postretirement benefit obligations

3,346

3,344

Noncurrent deferred tax liabilities

19,739

19,597

Other taxes payable

6,984

6,886

Other noncurrent liabilities

5,119

6,199

Total liabilities

102,006

105,381

Commitments and Contingencies

Preferred stock

43

45

Common stock

446

445

Additional paid-in capital

71,786

71,423

Employee benefit trusts

(2

(3

Treasury stock

(33,519

(31,801

Retained earnings

48,124

46,210

Accumulated other comprehensive loss

(3,622

(4,129

Total Pfizer Inc. shareholders equity

83,256

82,190

Equity attributable to noncontrolling interests

421

431

Total shareholders equity

83,677

82,621

Total liabilities and shareholders equity

185,683

188,002

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(millions of dollars)

April 1,

2012

April 3,

2011

Operating Activities:

Net income before allocation to noncontrolling interests

1,803

2,234

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by operating activities:

Depreciation and amortization

2,252

2,104

Share-based compensation expense

130

122

Asset write-offs and impairment charges

650

182

Deferred taxes from continuing operations

(404

(120

Benefit plan contributions in excess of expense

(71

(383

Other non-cash adjustments, net

(28

(19

Other changes in assets and liabilities, net of acquisitions and divestitures

(1,558

522

Net cash provided by operating activities

2,774

4,642

Investing Activities:

Purchases of property, plant and equipment

(254

(250

Purchases of short-term investments

(6,344

(3,352

Proceeds from redemptions and sales of short-term investments

8,119

2,553

Net proceeds from redemptions and sales of short-term investments with original

maturities of 90 days or less

623

5,983

Purchases of long-term investments

(1,184

(1,932

Proceeds from redemptions and sales of long-term investments

302

888

Acquisitions, net of cash acquired

(782

(3,169

Other investing activities

(29

Net cash provided by investing activities

451

725

Financing Activities:

Proceeds from short-term borrowings

1,561

2,682

Principal payments on short-term borrowings

(1,636

Net payments on short-term borrowings with original maturities of

90 days or less

(1,791

(584

Principal payments on long-term debt

(3

(3,878

Purchases of common stock

(1,659

(1,430

Cash dividends paid

(1,650

(1,591

Other financing activities

35

33

Net cash used in financing activities

(3,507

(6,404

Effect of exchange-rate changes on cash and cash equivalents

34

32

Net decrease in cash and cash equivalents

(248

(1,005

Cash and cash equivalents at beginning of period

3,182

1,735

Cash and cash equivalents at end of period

2,934

730

Supplemental Cash Flow Information:

Cash paid/(refunded) during the period for:

Income taxes

451

(134

Interest

508

687

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 26, 2012, and February 27, 2011. We have made certain reclassification adjustments to conform prior-period amounts to the current presentation, primarily related to certain inventories (see Note 8. Inventories) and the reclassification of certain investments (See Note 7. Financial Instruments).

On August 1, 2011, we completed the sale of our Capsugel business. In connection with our decision to sell our Capsugel business, we show the operating results of Capsugel as Discontinued operations net of tax for the three months ended April 3, 2011 (see Note 2B. Acquisitions and Divestitures: Divestitures).

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011.

B. Adoption of New Accounting Standards

The provisions of the following new accounting and disclosure standards were adopted as of January 1, 2012:

Presentation of comprehensive income in financial statements. As a result of adopting this new standard, we have presented a separate Condensed Consolidated Statement of Comprehensive Income.

An amendment to the guidelines on the measurement and disclosure of fair value that is consistent between U.S. GAAP and International Financial Reporting Standards. The adoption of this new standard did not have a significant impact on our financial statements.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Note 2. Acquisitions and Divestitures

A. Acquisitions

Alacer Corp.

On February 26, 2012, we completed our acquisition of Alacer Corp., a privately owned company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this acquisition, we recorded approximately $250 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand, $86 million in net deferred tax liabilities and approximately $130 million in Goodwill. The allocation of the consideration transferred has not been finalized.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Ferrosan Holding A/S

On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Due to the fact that financial information included in our fiscal year 2011 consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November 30, this acquisition is reflected in our condensed consolidated financials in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this acquisition, we recorded approximately $480 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands, $124 million in net deferred tax liabilities, and approximately $230 million in Goodwill. The allocation of the consideration transferred has not been finalized.

B. Divestitures

On August 1, 2011, we completed the sale of our Capsugel business for approximately $2.4 billion in cash. In connection with the decision to sell, the operating results associated with the Capsugel business are classified as Discontinued operations net of tax in the condensed consolidated statements of income for the three months ended April 3, 2011.

The components of Discontinued operations net of tax, virtually all of which relate to our former Capsugel business, follow:

Three Months Ended

(millions of dollars)

April 3,

2011

Revenues

177

Pre-tax income from discontinued operations

28

Provision for taxes on income(a)

(18

Income from discontinued operations net of tax

10

Discontinued operations net of tax

10

(a)

Deferred tax amounts are not significant.

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the three months ended April 3, 2011.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring businesses and restructuring and integrating acquired businesses and in connection with our global cost-reduction and productivity initiatives. For example:

for our cost-reduction and productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

for our acquisition activity, we typically incur costs that can include transaction costs, integration costs (such as expenditures for consulting and the integration of systems and processes) and restructuring charges, related to employees, assets and activities that will not continue in the combined company.

All of our businesses and functions can be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as functions such as information technology, shared services and corporate operations.

Since the acquisition of Wyeth on October 15, 2009, our cost-reduction initiatives announced on January 26, 2009, but not completed as of December 31, 2009, were incorporated into a comprehensive plan to integrate Wyeth s operations to generate cost savings and to capture synergies across the combined company. In addition, on February 1, 2011, we announced a new productivity initiative to accelerate our strategies to improve innovation and overall productivity in R&D by prioritizing areas with the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The components of costs associated with cost-reduction/productivity initiatives and acquisition activity follow:

Three Months Ended

(millions of dollars)

April 1,

2012

April 3,

2011

Transaction costs(a)

10

Integration costs(b)

100

179

Restructuring charges(c):

Employee termination costs

267

667

Asset impairments

218

25

Other

11

13

Restructuring charges and certain acquisition-related costs

596

894

Additional depreciation asset restructuring, recorded in our condensed consolidated statements of income as follows(d):

Cost of sales

79

172

Selling, informational and administrative expenses

Research and development expenses

259

64

Total additional depreciation asset restructuring

340

243

Implementation costs, recorded in our condensed consolidated statements of income as follows(e):

Selling, informational and administrative expenses

15

Research and development expenses

48

10

Total implementation costs

63

10

Total costs associated with cost-reduction initiatives and acquisition activity

999

1,147

(a)

Transaction costs represent external costs directly related to acquired businesses and primarily include expenditures for banking, legal, accounting and other similar services.

(b)

Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes.

(c)

From the beginning of our cost-reduction and transformation initiatives in 2005 through April 1, 2012, Employee termination costs represent the expected reduction of the workforce by approximately 59,400 employees, mainly in manufacturing and sales and research, of which approximately 46,300 employees have been terminated as of April 1, 2012. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

The restructuring charges for the three months ended April 1, 2012 are associated with the following:

Primary Care operating segment ($3 million), Specialty Care and Oncology operating segment ($3 million), Established Products and Emerging Markets operating segment ($3 million), Animal Health and Consumer Healthcare operating segment ($5 million), research and development operations ($12 million), manufacturing operations ($152 million) and Corporate ($318 million).

The restructuring charges for the three months ended April 3, 2011 are associated with the following:

Primary Care operating segment ($46 million), Specialty Care and Oncology operating segment ($35 million), Established Products and Emerging Markets operating segment ($4 million), Animal Health and Consumer Healthcare operating segment ($10 million), Nutrition operating segment ($2 million), research and development operations ($422 million), manufacturing operations ($75 million) and Corporate ($111 million).

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction and productivity initiatives.

The asset impairment charges included in restructuring charges in the first quarter of 2012 are based on an estimate of fair value for the related assets. A description follows:

Fair Value(a)

(millions of dollars)

April 1,

2012

Level 1

Level 2

Level 3

Impairment

Long-lived assets held-for-sale (b)

112

112

218

(a)

See Note 1C. Basis of Presentation and Significant Accounting Policies: Fair Value.

(b)

Reflects property, plant and equipment and other long-lived assets written down to their fair value of $112 million, less costs to sell of $2 million (a net of $110 million), in the first quarter of 2012. The impairment charges of $218 million are included in Restructuring charges and certain acquisition-related costs. Fair value is determined primarily using a market approach, with various inputs, such as recent sales transactions.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The components of restructuring charges follow:

Costs Incurred

Activity

Accrual

(millions of dollars)

2005-2012

Through

April 1,

2012(a)

As of

April 1,

2012(b)

Employee termination costs

10,869

8,638

2,231

Asset impairments

2,782

2,782

Other

1,033

949

84

Total restructuring charges

14,684

12,369

2,315

(a)

Includes adjustments for foreign currency translation.

(b)

Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($891 million).

Note 4. Other Deductions Net

The components of Other deductions net follow:

Three Months Ended

(millions of dollars)

April 1,

2012

April 3,

2011

Interest income(a)

(81

(105

Interest expense(a)

390

458

Net interest expense

309

353

Royalty-related income

(97

(171

Net gains on asset disposals

(7

(12

Certain legal matters, net(b)

814

501

Certain asset impairment charges(c)

432

157

Other, net

206

(1

Other deductions net

1,657

827

(a)

Interest income decreased in 2012 due to lower interest rates earned on investments. Interest expense decreased in 2012 due to lower long- and short-term debt balances and the effective conversion of some fixed-rate liabilities to floating-rate liabilities by using interest rate swaps.

(b)

In 2012, primarily relates to a $450 million charge in connection with an agreement-in-principle to settle a lawsuit by Brigham Young University related to Celebrex and charges for hormone-replacement therapy litigation. In 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 12. Commitments and Contingencies).

(c)

In 2012, primarily includes intangible asset impairments of approximately $395 million reflecting (i) $297 million of in-process research and development (IPR&D) that targeted autoimmune and inflammatory diseases, (ii) $45 million related to our Consumer Healthcare indefinite-lived brand, Robitussin, and (iii) $53 million of developed technology rights comprising the impairments of two assets. See also the table below. In 2011, relates to IPR&D for the treatment of a certain autoimmune and inflammatory disease. The impairment charges reflect, among other things, the impact of new scientific findings for IPR&D, and an increased competitive environment for Robitussin.

The intangible asset impairment charges included in Other deductions net in the first quarter of 2012 are based on an estimate of fair value for the related assets. A description follows:

Fair Value(a)

(millions of dollars)

April 1,

2012

Level 1

Level 2

Level 3

Impairment

Intangible assets IPR&D

297

Intangible assets Other

516

516

98

Total(b)(c)

516

516

395

(a)

See Note 1C. Basis of Presentation and Significant Accounting Policies: Fair Value.

(b)

Reflects intangible assets written down to their fair value of $516 million in the first quarter of 2012. The impairment charges of $395 million are included in Other deductions net. When we are required to determine the fair value of intangible assets other than goodwill, we use an income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with in-process research and development assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

(c)

Included in Identifiable intangible assets, less accumulated amortization.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was 29.4% for the first quarter of 2012, compared to 28.7% for the first quarter of 2011. The higher tax rate for the first quarter of 2012 is primarily due to a change in the jurisdictional mix of earnings and the impact of the expiration of the U.S. research and development tax credit.

B. Taxes on Items of Other Comprehensive Income

The components of taxes on Other comprehensive income follow:

Three Months Ended

(millions of dollars)

April 1,

2012

April 3,

2011

Taxes on Other Comprehensive Income

Foreign currency translation adjustments(a)

67

40

Unrealized holding gains/(losses) on derivative financial instruments

159

126

Reclassification adjustments for realized gains

(115

(194

44

(68

Unrealized gains/(losses) on available-for-sale securities

14

(3

Reclassification adjustments for realized losses

21

(2

Benefit plans: Actuarial gains/(losses)

Reclassification adjustments related to amortization

44

25

Reclassification adjustments related to curtailments and settlements, net

43

19

Other

(1

(27

86

17

Benefit plan: Prior service (costs)/credits and other

Reclassification adjustments related to amortization

(8

(7

Reclassification adjustments related to curtailments and settlements, net

(4

(4

Other

(2

(4

(14

(15

Tax expense/(benefit) on other comprehensive income

204

(28

(a)

Taxes are not provided for foreign currency translation relating to permanent investments in international subsidiaries.

C. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.

The United States is one of our major tax jurisdictions and we are regularly audited by the U.S. Internal Revenue Service (IRS):

With respect to Pfizer Inc., tax years 2006-2010 are currently under audit. Tax years 2011-2012 are not yet under audit. All other tax years are closed.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

With respect to Wyeth, tax years 2006 through the Wyeth acquisition date (October 15, 2009) are currently under audit. All other tax years are closed.

With respect to King Pharmaceuticals, Inc. (King), tax year 2008 is currently under audit, and for Alpharma Inc. (a subsidiary of King) tax years 2005-2007 are currently under audit. Tax years 2009 through the date of acquisition (January 31, 2011) are open but not under audit. All other tax years are closed. The open tax years and audits for King and its subsidiaries are not considered material to Pfizer.

In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (1998-2012), Japan (2006-2012), Europe (2002-2012, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany) and Puerto Rico (2007-2012).

Note 6. Accumulated Other Comprehensive Income/(Expense), Excluding Noncontrolling Interests

Changes, net of tax, in accumulated other comprehensive income/(expense) follow:

Net Unrealized Gain/(Losses)

Benefit Plans